Capsule Summary Slides

Share

Program Content

Activities

  • Neoadjuvant Osimertinib in EGFRm NSCLC
    Phase II Trial of Neoadjuvant Osimertinib in Stage I-IIIA EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2023

  • AGAIN
    Phase III AGAIN (JCOG1404/WJOG8214L) Trial: First-line EGFR-TKI Monotherapy vs EGFR-TKI and Inserted Cisplatin/Pemetrexed in Advanced Nonsquamous, EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2023

  • NEOTORCH
    Phase III NEOTORCH: Interim EFS Analysis of Perioperative Toripalimab + Platinum-Doublet CT vs Platinum-Doublet CT in Resectable Stage II/III NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2023

  • Pembro + CT in Pleural Mesothelioma
    Phase III Trial of Pembrolizumab + Chemotherapy vs Chemotherapy Alone in Treatment-Naive Pleural Mesothelioma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2023

  • KEYNOTE-671
    KEYNOTE-671: Pembrolizumab or Placebo + Platinum-Based Neoadjuvant Chemotherapy Followed by Resection and Adjuvant Pembrolizumab or Placebo in Early-Stage NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • CheckMate 9LA: 4-Yr Update
    CheckMate 9LA: 4-Yr Update of First-line Nivolumab + Ipilimumab + CT vs CT Alone in Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • TROPION-Lung02
    TROPION-Lung02: Datopotamab Deruxtecan + Pembrolizumab ± Platinum Chemotherapy in Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • KEYNOTE-789
    Phase III KEYNOTE-789: Pemetrexed/Platinum Chemotherapy ± Pembrolizumab in TKI-Resistant, EGFR-Mutated, Metastatic Nonsquamous NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • SWOG S1929
    Phase II SWOG S1929: Maintenance Atezolizumab ± Talazoparib for SLFN11-Positive Extensive-Stage SCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • INSIGHT 2 Trial Results
    INSIGHT 2: Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • ADAURA: Final OS Analysis
    ADAURA: OS Analysis of Adjuvant Osimertinib vs Placebo After Complete Resection in Stage IB-IIIA EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • LUNAR: TTFields in NSCLC
    Phase III LUNAR: Tumor Treating Fields + Standard Second-line Therapy in Metastatic NSCLC With Progression On/After Platinum-Based Therapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2023

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure